Figure 2.

Knockdown of NAT10 confirms remodelin attenuates doxorubicin resistance in BC cells by inhibiting NAT10. A. BC cells were treated with different concentrations of doxorubicin (0, 0.0625, 0.125, 0.25, 0.5, 1.0 μg/mL), then transfected with the NAT10 siRNA, negative control siRNA, or NAT10 siRNA and treated with remodelin. Cell viability was examined using the CCK-8 assay. B. Western blotting was used to confirm the knockdown efficiency of the NAT10 siRNA; GAPDH was used as the internal control.